An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have previously identified a subset of cancers harbouring homozygous deletion of the glycolytic enzyme enolase (ENO1) that have exceptional sensitivity to inhibition of its redundant paralogue, ENO2, through a therapeutic strategy known as collateral lethality. Here, we show that a small-molecule enolase inhibitor, POMHEX, can selectively kill ENO1-deleted glioma cells at low-nanomolar concentrations and eradicate intracranial orthotopic ENO1-deleted tumours in mice at doses well-tolerated in non-human primates. Our data provide an in vivo proof of principle of the power of collateral lethality in precision oncology and demonstrate the utility of POMHEX for glycolysis inhibition with potential use across a range of therapeutic settings. Oncogenic transformation can render cancer cells dependent on aberrant expression of glycolytic enzyme isoforms. Lin et al. describe a novel enolase inhibitor, POMHEX, that can selectively kill ENO1-deleted glioblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Passenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339
Self-citationSF2312 is a natural phosphonate inhibitor of enolase
Leonard, P. G., Satani, N., Maxwell, D., Lin, Y.-H., Hammoudi, N., Peng, Z., Pisaneschi, F., Link, T. M., Lee, G. R., Sun, D., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2195 · Cited by 96
Self-citation
Cited by
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Modulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48
Itraconazole inhibits tumor growth via CEBPB‐mediated glycolysis in colorectal cancer
Zhang, Y., Li, L., Chu, F., Wu, H., Xiao, X., Ye, J., & Li, K. (2024) · Cancer Science · doi:10.1111/cas.16082 · Cited by 19
“14 In our study, we found that itraconazole could repress the expression of a new transcription factor (TF) Enhancer Binding Protein Beta (CEBPB), thus inhibiting glycolysis and tumor growth by controlling ENO1 expression.”
Background
Metadata
- Authors
- Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., Maxwell, D., Peng, Z., Leonard, P. G., Czako, B., Pisaneschi, F., Mandal, P., Sun, Y., Zielinski, R., Pando, S. C., Wang, X., Tran, T., Xu, Q., Wu, Q., Jiang, Y., Kang, Z., Asara, J. M., Priebe, W., Bornmann, W., Marszalek, J. R., DePinho, R. A., & Muller, F. L.
- Venue
- Nature Metabolism
- Published
- 2020-11-23
- Volume
- 2
- Issue
- 12
- Pages
- 1413-1426
- ISSN
- 2522-5812 (ISSN-L)
- OpenAlex
- W3110472159
- Cited by
- 91
- References
- 4
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. https://app.cochat.ai/papers/10.1038/s42255-020-00313-3
- The paper
- Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., Maxwell, D., Peng, Z., Leonard, P. G., Czako, B., Pisaneschi, F., Mandal, P., Sun, Y., Zielinski, R., Pando, S. C., . . . Muller, F. L. (2020). An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism. https://doi.org/10.1038/s42255-020-00313-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.